Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase (MurF) is an essential bacterial enzyme involved in the biosynthesis of peptidoglycan, a critical component of the bacterial cell wall. It catalyzes the final step in the formation of UDP-N-acetylmuramoyl-pentapeptide, which serves as a precursor for murein (peptidoglycan) synthesis. MurF is responsible for catalyzing the ATP-dependent addition of D-Ala–D-Ala dipeptide to UDP-N-acetylmuramoyl-tripeptide during peptidoglycan biosynthesis. The activity of MurF is crucial for maintaining cell wall integrity and thus bacterial viability. It is an attractive target for antibacterial drug development due to its essential role and lack of human homologs.
Inhibition of peptidoglycan biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase (MurF).